F.D.A. Approves Blood Test for Colon Cancer Detection

Category: Health

The Shield blood test by Guardant Health detects 83% of colorectal cancers but only 13% of dangerous polyps, making it less effective than colonoscopies. Approved by the FDA for individuals aged 45 and over, it aims to increase screening rates for colorectal cancer, which is the second leading cause of cancer-related deaths in the U.S. Despite its limitations, the test offers a simpler alternative to traditional screening methods.

Keywords: colorectal cancer, blood test, Guardant Health

Source: The New York Times

Update At: 7/30/2024

Related Sources